DNLI FY 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M-85.5% YoY

Gross Profit

$49M100.0% margin

Operating Income

-$296M-607.8% margin

Net Income

-$291M-597.2% margin

EPS (Diluted)

$-2.39

Cash Flow

Operating Cash Flow

-$211M

Free Cash Flow

-$220M

Stock-Based Comp.

$85M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$442M

Stockholders' Equity

$962M

Cash & Equivalents

$293M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$336M	-85.5%
Gross Profit	$49M	$336M	-85.5%
Operating Income	-$296M	$63M	-571.6%
Net Income	-$291M	$71M	-508.5%